Alnylam Pharmaceuticals (ALNY) Trading Down 6.9%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price traded down 6.9% during mid-day trading on Friday . The stock traded as low as $84.29 and last traded at $84.52. 734,055 shares were traded during trading, a decline of 11% from the average session volume of 822,006 shares. The stock had previously closed at $90.74.

Several equities analysts recently issued reports on the stock. Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 6th. Evercore ISI upgraded shares of Alnylam Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Wednesday, March 6th. Morgan Stanley upgraded shares of Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price target on the stock in a research report on Tuesday, March 5th. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $135.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, February 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $132.06.

The company has a current ratio of 6.69, a quick ratio of 6.56 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $8.98 billion, a P/E ratio of -11.17 and a beta of 2.61.



Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 7th. The biopharmaceutical company reported ($2.09) EPS for the quarter, topping the consensus estimate of ($2.27) by $0.18. Alnylam Pharmaceuticals had a negative net margin of 1,016.58% and a negative return on equity of 50.82%. The business had revenue of $21.00 million for the quarter, compared to analyst estimates of $18.03 million. During the same quarter in the previous year, the firm posted ($1.20) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was down 44.6% on a year-over-year basis. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -9.02 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of ALNY. ETF Managers Group LLC lifted its stake in shares of Alnylam Pharmaceuticals by 15.7% in the fourth quarter. ETF Managers Group LLC now owns 1,086 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 147 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 0.9% in the fourth quarter. Advisors Asset Management Inc. now owns 17,883 shares of the biopharmaceutical company’s stock worth $1,304,000 after buying an additional 155 shares in the last quarter. M&T Bank Corp lifted its stake in shares of Alnylam Pharmaceuticals by 3.7% in the fourth quarter. M&T Bank Corp now owns 5,305 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 188 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co lifted its stake in shares of Alnylam Pharmaceuticals by 40.0% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 200 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 10.2% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,778 shares of the biopharmaceutical company’s stock valued at $275,000 after purchasing an additional 350 shares during the last quarter. 85.69% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This article was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://dakotafinancialnews.com/2019/03/24/alnylam-pharmaceuticals-alny-trading-down-6-9.html.

Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Featured Story: How to Invest in an Index Fund

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.